BioSpace News Archive

Transcat, Inc. announced that Lee D. Rudow, President and Chief Executive Officer, and Mark A. Doheny, Chief Financial Officer, will present and be available for investor meetings at the Sidoti Virtual Micro Cap Investor Conference on Wednesday, December 8, 2021.

Total funding for this collaborative research project is about $3.5 million and is made possible in part with the financial support of the Ministère de l’Économie et de l’Innovation (MEI) as part of CQDM’s SynergiQC program and from an exceptional donation made by Mr. Normand Lord to the IUCPQ Foundation.

As the pandemic has evolved rapidly, so too have the FDA’s views and requirements on what pre-clinical and non-clinical data sets will be necessary to support initiation of a first in human clinical trial for COVID-19. In written responses to the questions provided by the Company, the FDA addressed PharmaDrug’s questions related to manufacturing, safety/toxicology, pre-clinical efficacy studies, clinical trial design, and rationale necessary to support subsequent human clinical trials.

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Soundbite Medical Solutions Inc. (SBMS), today announced that the United States Patent and Trademark Office has issued US patent No. 11,179,169, entitled “Device for delivering mechanical waves through a balloon catheter”.

GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa.

Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. (“EVT”) are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the study design for SAPPHIRE, a Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin.

Quidel Corporation issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron.

Krystal Biotech, Inc., the leader in redosable gene therapies for rare diseases, announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share.